Prana co-founder addresses US Senate
Tuesday, 08 July, 2008
The co-founder of Prana Biotechnology [ASX: PBT], Dr Rudolph Tanzi, has delivered testimony on Alzheimer's disease before the US Senate Special Committee on Ageing.
The hearings were held to discuss the growing crisis of Alzheimer's disease and to look for ways the US can accelerate its efforts against the disease.
Tanzi, an internationally recognised authority on Alzheimer's disease who co-discovered three of the four known genes that cause it, presented information on differing Abeta-targeted therapeutic approaches, and commented upon the ongoing clinical trials in Alzheimer's disease.
Prana's theories concerning the interaction between metals and the protein Abeta in the brain are the basis of the company's treatments for Alzheimer's and other neurodegenerative diseases.
Heart muscle regeneration genes mapped
Researchers have uncovered insights into how stem cells develop and mature into heart muscle...
The cause of 2022's mpox outbreak revealed
Researchers have discovered that the strain of mpox behind the 2022 outbreak was a weakened form...
New gene therapy treats liver disorder in growing children
Researchers have developed a genome-editing approach that repairs a faulty gene directly at its...
